Despite widespread optimism about the tax cut bill racing through Congress, biopharma insiders across the U.S. say they’re not expecting to add new jobs at their companies in the coming year, a new STAT Plus survey finds.
Nearly 6 in 10 respondents said it’s unlikely their companies will be expanding. Nonetheless, they remain bullish on the industry at large, with more than half expressing strong confidence that biotech will have a good year.
About the Author Reprints
